These days were instituted by the World Health Organization (WHO) in order to raise awareness about these diseases, in addition to giving visibility to these conditions among the general population.
He multiple myeloma (MM) it is the second most common blood cancer after non-Hodgkin lymphomas;1 it is not as common as breast, colon, lung, or prostate cancers. What happens in the body with this disease is an excessive growth of plasma cells in the bone marrow, which are an important component of the immune system.2
MM may not present symptoms in the initial stage of the disease, but when they do appear, they can range from pain in the bones, especially in the spine or chest, nausea, constipation, loss of appetite, disorientation or mental confusion, fatigue , frequent infections, weight loss, weakness or numbness in the legs and excessive thirst.3
Multiple myeloma is the cancer that most often affects the skeleton. It is estimated that 80 to 90% of patients with MM develop osteolytic-type bone lesions during the course of their disease, which are associated with severe and debilitating pain, hypercalcemia, and bone complications, primarily pathological-type fractures.4
In 2022, Amgen Mexico conducted a study on the economic evaluation of the use of denosumab compared to zoledronic acid (AZ) or no treatment for the prevention of skeletal-related events (SRE) in patients with multiple myeloma in Mexico. The results of the study arroThey found that the purchase of denosumab represented only 11% of the total cost in that group. Approximately 89% of the difference between the acquisition cost of denosumab and that of AZ, $200,430 MXN, is offset by the sum of the savings achieved by reducing the frequency of SREs, the decrease in the cost of anti-myeloma treatment, and the benefit of not require intravenous infusions for administration. In conclusion, in patients with MM, denosumab represents a cost-effective intervention compared to zoledronic acid or in the absence of treatment.5
For her part, the primary immune thrombocytopenia (PIT) is a bleeding disorder that affects the blood’s ability to clot due to too low a number of blood cells called platelets.6
A person with TIP may have bleeding under the skin or from injury and damage to the blood vessels, often purple bruises caused by bleeding from small blood vessels 7under the skin, these bruises can appear on the skin or on mucous membranes; It can also cause bleeding that looks like red or purple pinpoint-sized spots on the skin (petechiae).8
To learn more about the cost of this disease, Amgen Mexico conducted a study on the economic evaluation of the administration of thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia in Mexico. Thrombopoietin receptor agonists stimulate platelet production without the production of autoreactive antithrombopoietin antibodies. For the study, 3 competing interventions were compared: romiplostin, eltrombopag, and the observe and rescue (W & R) method, which consists of administering only rescue treatment in cases of bleeding events that warrant it.9
The results of the study showed that the lowest costs were with observe and rescue ($177,545 MXN), followed by romiplostim ($260,768 MXN) and eltrombopag ($271,738 MXN). By far, romiplostim had the highest proportion of patients with an overall platelet response. In conclusion, the average cost per patient achieving overall platelet response was better with romiplostim. 10
Amgen Mexico reinforces its commitment and investment in research and development of alternatives through biotechnology so that more people have access to innovative treatments for diseases such as multiple myeloma and primary immune thrombocytopenia, inviting them to regularly attend their trusted doctor for prevent this type of suffering and thus they can have a better quality of life.
Visit: https://www.amgen.com.mx and follow us on X (Before Twitter) @AmgenMexicoFacebook Amgen Mexico and LinkedIn Amgen
To learn more about the studies visit: Economic evaluation of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Mexico and Economic evaluation of the administration of thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia in Mexico.
1 ESMO, Anticancer Found. ESMO/FCC Patient Guide Series. Retrieved August 23, 2023 from: https://www.esmo.org/content/download/138236/2546627/file/ES-Multiple-Myeloma-Guide-for-Patients.pdf
2 American Cancer Society. What is multiple myeloma? Consulted on April 13, 2023: https://www.cancer.org/es/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html
3 Mayo Clinic. Multiple myeloma. Symptoms and causes. Retrieved August 23, 2023 from: https://www.mayoclinic.org/es-es/diseases-conditions/multiple-myeloma/ symptoms-causes/syc-20353378
4 Economic evaluation of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Mexico. Retrieved August 23, 2023 from: https://www.gamo-smeo.com/frame_eng.php?id=282
5 Economic evaluation of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Mexico. Retrieved August 23, 2023 from: https://www.gamo-smeo.com/frame_eng.php?id=282
6 Immune thrombocytopenia. Mayo Clinic. Retrieved August 23, 2023 from: https://www.mayoclinic.org/es-es/diseases-conditions/idiopathic-thrombocytopenic-purpura/symptoms-causes/syc-20352325
7 Immune thrombocytopenia. Mayo Clinic. Retrieved August 23, 2023 from: https://www.mayoclinic.org/es-es/diseases-conditions/idiopathic-thrombocytopenic-purpura/symptoms-causes/syc-20352325
8 Primary immune thrombocytopenia (PIT) in adults in Mexico: national characteristics and their relationship with the international literature. Accessed August 23, 2023:
https://www.anmm.org.mx/GMM/2014/n4/GMM_150_2014_4_279-288.pdf
9 Economic evaluation of the administration of thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia in Mexico. Retrieved August 23, 2023 from: https://revistadehematologia.org.mx/article/evaluacion-economica-de-la-administracion-de-agonistas-del-receptor-de-trombopoietina-en-pacientes-adultos-con-trombocytopenia-inmunitaria-primaria-en- Mexico/
10 Economic evaluation of the administration of thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia in Mexico. Retrieved August 23, 2023 from: https://revistadehematologia.org.mx/article/evaluacion-economica-de-la-administracion-de-agonistas-del-receptor-de-trombopoietina-en-pacientes-adultos-con-trombocytopenia-inmunitaria-primaria-en- Mexico/
Number:
MEX-531-0823-80001 August 2023
Educational material, not promotional.